Ultrasound to predict brain pressure in lung cancer patients
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This study uses a special ultrasound scan of the head to help doctors predict pressure inside your skull and how your disease may progress. It is for people with non-small cell lung cancer that has spread to the lining of the brain and spinal cord, and who have already had spinal chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older.
- Have a confirmed diagnosis of non-small cell lung cancer (NSCLC) that has spread to the membranes around the brain or spinal cord (leptomeningeal metastasis).
- Have had a lumbar puncture (spinal tap) and chemotherapy delivered directly into the spinal fluid at the study center.
- Be generally functional—able to manage daily activities with some help.
- Meet basic blood test levels: infection-fighting cells (neutrophils) ≥ 1500, hemoglobin ≥ 9, platelets ≥ 100.
- Have adequate liver and kidney function.
- Not have active bleeding, blood-clotting disorders, or recent blood clots. Exclude if you have had uncontrolled seizures, a history of other cancers, or recent serious surgery/trauma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation to the whole brain, immunotherapy, and chemotherapy given through a lumbar puncture. It is for people with lung cancer that has spread to the lining of the brain and has not responded to standard treatments.
This trial tests a treatment given directly into the fluid around the brain and spinal cord (intrathecal injection) using two drugs—pemetrexed and bevacizumab—for people with non-small cell lung cancer that has spread to that area (leptomeningeal metastases). It may be an option if your current treatment is no longer working.
This trial looks at spinal fluid (also called CSF) in adults with EGFR-mutant lung cancer that has spread to the lining around the brain/spinal cord. The goal is to better understand the disease and what the spinal fluid tests may show to guide care.
This trial tests a stronger dose of an EGFR-targeted drug combined with bevacizumab and chemotherapy into the spinal fluid for patients with non-small cell lung cancer that has spread to the lining of the brain and is no longer responding to standard treatment.
This study tests whether giving a higher dose of an EGFR-targeted pill, either alone or with a chemotherapy drug injected into the fluid around the spinal cord, can control lung cancer that has spread to the lining of the brain (called leptomeningeal metastases). It is for people whose cancer has gotten worse in the brain lining while on a standard dose of this type of medication.
This trial tests a combination of proton radiation to the brain and spine plus chemotherapy given directly into the fluid around the brain and spinal cord. It is for people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer) that has spread to the lining of the brain and has continued to grow despite taking a third-generation TKI medicine like osimertinib.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.